prikaz prve stranice dokumenta Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint
Rad je dostupan svim korisnicima iz sustava znanosti i visokog obrazovanja RH
Znanstveni rad - Izvorni znanstveni rad
Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint
Oncogene, 39 (2020), 17; 344-357. https://doi.org/10.1038/s41388-020-1231-6
Oršolić, Ines; Bursać, Slađana; Jurada, Deana; Drmić Hofman, Irena; Dembić, Zlatko; Bartek, Jiri; Mihalek, Ivana; Volarević, Siniša

Citirajte ovaj rad

Oršolić, I., Bursać, S., Jurada, D., Drmić Hofman, I., Dembić, Z., Bartek, J. ... Volarević, S. (2020). Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint. Oncogene, 39. (17), 344-357. doi: 10.1038/s41388-020-1231-6

Oršolić, Ines, et al. "Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint." Oncogene, vol. 39, br. 17, 2020, str. 344-357. https://doi.org/10.1038/s41388-020-1231-6

Oršolić, Ines, Slađana Bursać, Deana Jurada, Irena Drmić Hofman, Zlatko Dembić, Jiri Bartek, Ivana Mihalek i Siniša Volarević. "Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint." Oncogene 39, br. 17 (2020): 344-357. https://doi.org/10.1038/s41388-020-1231-6

Oršolić, I., et al. (2020) 'Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint', Oncogene, 39(17), str. 344-357. doi: 10.1038/s41388-020-1231-6

Oršolić I, Bursać S, Jurada D, Drmić Hofman I, Dembić Z, Bartek J, i sur.. Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint. Oncogene [Internet]. 27.02.2020. [pristupljeno 12.11.2024.];39(17):344-357. doi: 10.1038/s41388-020-1231-6

I. Oršolić, et al., "Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint", Oncogene, vol. 39, br. 17, str. 344-357, Veljača 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:956160. [Citirano: 12.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:956160
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint
AutorInes Oršolić
AutorSlađana Bursać
AutorDeana Jurada
AutorIrena Drmić Hofman
AutorZlatko Dembić
AutorJiri Bartek
AutorIvana Mihalek
AutorSiniša Volarević
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za molekularnu medicinu i biotehnologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Perturbations in ribosome biogenesis have been associated with cancer. Such aberrations activate p53 through the RPL5/RPL11/5S rRNA complex-mediated inhibition of HDM2. Studies using animal models have suggested that this signaling pathway might constitute an important anticancer barrier. To gain a deeper insight into this issue in humans, here we analyze somatic mutations in RPL5 and RPL11 coding regions, reported in The Cancer Genome Atlas and International Cancer Genome Consortium databases. Using a combined computational and statistical approach, complemented by a range of biochemical and functional analyses in human cancer cell models, we demonstrate the existence of several mechanisms by which RPL5 mutations may impair wild-type p53 upregulation and ribosome biogenesis. Unexpectedly, the same approach provides only modest evidence for a similar role of RPL11, suggesting that RPL5 represents a preferred target during human tumorigenesis in cancers with wild-type p53. Furthermore, we find that several functional cancer-associated RPL5 somatic mutations occur as rare germline variants in general population. Our results shed light on the so-far enigmatic role of cancer-associated mutations in genes encoding ribosomal proteins, with implications for our understanding of the tumor suppressive role of the RPL5/RPL11/5S rRNA complex in human malignancies.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaOncogene
Brojčani podacivol. 39, br. 17, str. 344-357
p-ISSN0950-9232
e-ISSN1476-5594
DOIhttps://doi.org/10.1038/s41388-020-1231-6
URN:NBNurn:nbn:hr:184:956160
Datum objave elektroničkog izdanja2020-02-27
ProjektŠifra: 09.01/220
Naziv (hrvatski): Uloga ribosomskih proteina L5 i L11 u aktivaciji tumor supresora p53 i patogenezi zloćudnih tumora
Voditelj: Siniša Volarević
Pravna nadležnost: Hrvatska
Financijer: HRZZ
Linija financiranja: IS
ProjektŠifra: IP-2016-06-2079
Naziv (hrvatski): Uloga heterozigotnosti gena za ribosomski protein S6 u zloćudnoj preoprazbi stanica
Kratica: ONCO-RIB
Voditelj: Siniša Volarević
Pravna nadležnost: Hrvatska
Financijer: HRZZ
Linija financiranja: IP
URL dokumentahttp://www.nature.com/articles/s41388-020-1231-6
Vrsta resursaTekst
Prava pristupaOgraničen pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2020-03-10 08:46:32